Skip to main content
Global Bioenergies logo

Global Bioenergies — Investor Relations & Filings

Ticker · ALGBE ISIN · FR0011052257 LEI · 969500H46XRAMTMVB676 PA Manufacturing
Open in API
Filings indexed 443 across all filing types
Latest filing 2022-02-01 Regulatory Filings
Country FR France
Listing PA ALGBE

About Global Bioenergies

https://www.global-bioenergies.com/?lan…

Global Bioenergies develops and commercializes a process to convert renewable resources, such as plant-based sugars and agricultural waste, into isobutene. The company's proprietary technology utilizes fermentation and synthetic biology to produce this key hydrocarbon, which serves as a platform molecule for various applications. The bio-isobutene can be converted into ingredients for the cosmetics industry, specialty chemicals, and renewable fuels. A primary strategic focus is the production of Sustainable Aviation Fuel (SAF) to support the decarbonization of the aviation sector. The process provides a bio-based alternative to petroleum-derived hydrocarbons, aiming to reduce CO2 emissions and dependence on fossil fuels.

Recent filings

Filing Released Lang Actions
Global Bioenergies - 500 000 euros de subvention accordés à Global Bioenergies par la Région Grand Est dans le cadre du plan France Relance
Regulatory Filings Classification · 100% confidence The document is a press release dated February 1, 2022, announcing that Global Bioenergies received a 500,000 euro subsidy from the Grand Est Region under the France Relance plan to complete the construction of its Pomacle unit and launch commercialization for the cosmetics industry. This announcement details specific financial support (a subsidy/grant) related to capital expenditure and future commercialization efforts, rather than reporting periodic financial results (ER/IR), providing audit details (AR), or announcing management changes (MANG). It is a specific announcement regarding financing and capital structure development, fitting best under 'Capital/Financing Update' (CAP). It is not a general regulatory filing (RNS) because it fits a more specific category.
2022-02-01 French
TP ICAP Midcap initiates coverage of Global Bioenergies share
Regulatory Filings Classification · 97% confidence The document is a press release dated January 31, 2022, announcing that TP ICAP Midcap has initiated coverage of Global Bioenergies and published a detailed analysis for its clients. The text itself is an announcement about the existence and availability of an analysis/report from a third party (TP ICAP Midcap), rather than the analysis itself, a formal financial filing (like 10-K or IR), or a transcript. Since it is an announcement regarding the publication of external analysis/information intended for investors, it fits best under the general category of investor relations communication. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for general corporate announcements that don't fit specific categories like ER, DIV, or CT, especially when the core content is an announcement about external coverage/analysis publication. However, since the document is essentially announcing the release of a detailed analysis/report by a third party, and it is not a standard regulatory filing, 'Report Publication Announcement' (RPA) might also be considered if the focus is on the *announcement* of the report's availability. Given the context of initiating coverage and publishing an analysis, RNS (General regulatory/corporate announcement) is a strong fit, but RPA specifically covers announcements about report publication. Since this is an announcement about a third-party analysis being published, and it's not a standard company financial report, RNS is the safest general corporate announcement category.
2022-01-31 English
TP ICAP Midcap initie la couverture du titre Global Bioenergies
Report Publication Announcement Classification · 99% confidence The document is a press release dated January 31, 2022, announcing that TP ICAP Midcap has initiated coverage of Global Bioenergies and published a detailed analysis for its clients. The text itself is an announcement about the existence of an analysis/report, not the full analysis or a standard regulatory filing like 10-K or IR. Since it is an announcement related to investor relations and the publication of external analysis, it fits best under the general category for regulatory announcements or investor communications that don't match a more specific code. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release announcing third-party research coverage, although 'Report Publication Announcement' (RPA) is also plausible if the focus is strictly on the publication event. However, RNS is often used for general market-moving news releases that aren't strictly financial results or mandatory disclosures. Given the context of initiating coverage and publishing an analysis, RNS serves as a strong general announcement category.
2022-01-31 French
Global Bioenergies - Bilan annuel du contrat de liquidité au 31/12/2021
Transaction in Own Shares Classification · 95% confidence The document is titled "Bilan annuel du contrat de liquidité au 31/12/2021" (Annual balance sheet of the liquidity contract as of 12/31/2021). It details the status of a liquidity contract managed by a broker (Gilbert Dupont) and reports on the number of shares and cash held under this contract, as well as the trading activity (purchases and sales) during the second half of 2021. This type of regular reporting concerning share trading activities by the company itself (or its designated agent) under a liquidity agreement is specifically related to the company's own shares. This aligns best with the 'Transaction in Own Shares' category (POS), which covers share repurchase/issuance activities, including those managed via liquidity contracts. It is not a general regulatory filing (RNS), an earnings release (ER), or a formal annual report (10-K).
2022-01-10 French
Global Bioenergies réalise avec succès une levée de fonds d’un montant global de 14,5 millions d’euros
Share Issue/Capital Change Classification · 99% confidence The document is a press release titled "Global Bioenergies réalise avec succès une levée de fonds d'un montant global de 14,5 millions d'euros" (Global Bioenergies successfully raises funds totaling 14.5 million euros). The text explicitly details a capital increase ('augmentation de capital') involving the issuance of new shares to institutional investors and individuals. This activity directly relates to fundraising, financing activities, and changes in capital structure. According to the definitions, this aligns perfectly with the 'Capital/Financing Update' category (Code: CAP). It is not an earnings release (ER), an annual report (10-K), or a simple announcement of a report (RPA/RNS), as it contains the substantive details of the financing event itself.
2021-12-14 French
Global Bioenergies successfully completes a fundraising for a total amount of €14.5 million
Share Issue/Capital Change Classification · 99% confidence The document is titled "Global Bioenergies successfully completes a fundraising for a total amount of €14.5 million" and details the successful completion of a capital increase involving institutional and retail investors. It explicitly discusses the issuance of new ordinary shares, the resulting change in share capital structure, and the purpose of the funds raised. This content directly relates to financing activities and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document is a press release announcing the completion, not just an announcement of a future report (RPA/RNS).
2021-12-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.